Arthritis News Archive

Merrimack Pharmaceuticals Initiates Enrollment In A Phase 2 Study Of MM-093 In Patients With Rheumatoid Arthritis (Medical News Today)
Merrimack Pharmaceuticals, Inc. today announced the initiation of a Phase 2 study to evaluate the safety and efficacy of its immunomodulator, MM-093, in patients suffering from rheumatoid arthritis (RA). MM-093, Merrimack's lead product, is a recombinant version of human alpha-fetoprotein (AFP). [click link for full article]

Chondroitin no better than placebo for arthritis: review (CBC)
The dietary supplement chondroitin is ineffective at relieving knee or hip pain caused by arthritis and its use should be discouraged, a review concludes.

Pipeline Insight: Disease Modification in Rheumatoid Arthritis - Competition for the anti-TNF failure patient ... (Pharmaceutical Business Review)
Introduction The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade.

Treatments: Study Sees Little Benefit in Chondroitin for Arthritis (New York Times)
A new study suggests that chondroitin may not offer any real benefit to sufferers of arthritis pain.

Chondroitin No Help for Arthritis Pain (Fox News)
A new study in the Annals of Internal Medicine finds chondroitin is no better than a sugar pill to treat arthritis

Chondroitin No Help for Arthritis Pain (MedicineNet.com)
Title: Chondroitin No Help for arthritis Pain Category: Health News Created: 4/17/2007 Last Editorial Review: 4/17/2007